E Fund Management Co. Ltd. Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

E Fund Management Co. Ltd. lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,455 shares of the medical device company’s stock after buying an additional 331 shares during the period. E Fund Management Co. Ltd.’s holdings in DexCom were worth $618,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the second quarter worth about $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares during the period. DSM Capital Partners LLC purchased a new position in shares of DexCom in the fourth quarter worth about $28,000. Crewe Advisors LLC bought a new stake in shares of DexCom in the first quarter worth about $29,000. Finally, Riverview Trust Co bought a new stake in shares of DexCom in the first quarter worth about $32,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock valued at $201,708 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the company. UBS Group cut their target price on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Oppenheimer cut their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Stock Performance

Shares of DXCM opened at $69.46 on Thursday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The business’s 50 day moving average price is $79.87 and its 200-day moving average price is $110.26. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $27.62 billion, a P/E ratio of 44.81, a P/E/G ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the firm posted $0.34 EPS. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.